This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tasmar

Mylan Inc.

Drug Names(s): Tolcapone

Description: Tasmar is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). In mammals, COMT is distributed throughout various organs. The highest activities are in the liver and kidney. COMT also occurs in the heart, lung, smooth and skeletal muscles, intestinal tract, reproductive organs, various glands, adipose tissue, skin, blood cells and neuronal tissues, especially in glial cells. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa catalyzing the metabolism to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery.

The precise mechanism of action of Tasmar is unknown, but it is believed to be related to its ability to inhibit COMT and alter the plasma pharmacokinetics of levodopa.

Deal Structure: In May 2004, Valeant Pharmaceuticals announced it acquired the rights to Tasmar in the U.S. and certain non-European Union (EU) markets where it was sold from F. Hoffmann-La Roche for $13.5 million in cash, plus royalties. Under the terms of the agreement, Valeant Pharmaceuticals acquired the rights to manufacture, market and distribute Tasmar in these countries. Valeant acquired and will continue use of the Tasmar trademark.

In September 2004, Valeant Pharmaceuticals announced it acquired the European Union(EU) rights to Tasmar from Roche for $11.4 million, plus royalties. The acquisition provides Valeant with global rights to Tasmar.

In August 2008, Valeant Pharmaceuticals announced that the Company had agreed to sell its business operations located in Western Europe, Eastern Europe including Russia, and certain export markets to Meda AB. Under the terms of the agreement, Meda will pay $392 million in cash for the Valeant subsidiaries in those markets, and the rights to all...See full deal structure in Biomedtracker

Partners: Roche Holding AG


Tasmar News

Pink Sheet Roche Tasmar


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug